Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 8 other studies
205people with obesity, in this paper
The trial randomly assignedassigned by chance
SGLT2i
control
Probably raised total cholesterol+0.13
Probably raised low-density cholesterol+0.18
Probably increased genitourinary adverse events11×
randomisedthe abstract, start to end
… total testosterone (mean difference=-0.10 [-0.19, -0.01], P=0.03), free …
Total cholesterol (mean difference=0.13 [0.01, 0.26], P=0.04) and low-density cholesterol (MD=0.18 [0.06, 0.31], P=0.003) …
… were more common in the SGLT2i group (OR=10.88 [1.33, 89.14], P= 0.03).
← favours treatmentfavours comparator →
could be chanceTotal testosteroneSGLT2i vs control
−0.10−0.19 to −0.01
Total cholesterolSGLT2i vs control
0.130.01–0.26
Low-density cholesterolSGLT2i vs control
0.180.06–0.31
Genitourinary adverse eventsSGLT2i vs control
OR 10.881.33–89.1
SGLT2 inhibitorsLipidsAdverse events & safetyInflammation & biomarkers
SGLT2 inhibitors × lipidshelps?replicated
unlikelylikely
1.00not counted
SGLT2 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
← favours comparatorfavours treatment →
1 / 7